Proteases

MD5 is a selective inhibitor of TMPRSS6, demonstrating an IC50 of 22 nM and a Ki of 3.4 nM for recombinant human TMPRSS6. It shows limited inhibition of Matriptase, with an IC50 of 352 nM and a Ki of 99.2 nM, and a weak effect on thrombin (Ki of 120 nM). Due to its favorable target specificity and initial drug-like properties, MD5 is suitable for research into iron overload diseases, including hereditary hemochromatosis and β-thalassemia.

AMG-126737 is a highly selective oral inhibitor of human mast cell tryptase, exhibiting a Ki value of 90 nM. This compound effectively suppresses both early and late-phase bronchoconstriction in sheep models. AMG-126737 is an important tool in the research of asthma and allergic diseases, enabling investigations into novel therapeutic strategies for these conditions.

Thrombin inhibitor 7 is a selective inhibitor of Factor XIIa (FXIIa) with an IC50 value of 28 nM, demonstrating strong potency. It exhibits minimal activity against Factor XIa (FXIa) with an IC50 value exceeding 132 µM. This compound's low cytotoxicity makes it suitable for various biochemical studies and therapeutic research focused on coagulation pathways.

PAI-1, or Plasminogen Activator Inhibitor-1, is a critical regulator of fibrinolysis, functioning primarily as an inhibitor of tissue-type (tPA) and urokinase-type (uPA) plasminogen activators. As a member of the Ser Protease inhibitor superfamily, PAI-1 exhibits significant antiprotease activity. This reagent is widely utilized in research applications related to thrombosis, tissue remodeling, and cancer metastasis, providing valuable insights into the mechanisms underlying these complex biological processes.

TNIK-IN-4 is a selective inhibitor of TNIK (TRAF2 and NCK interacting kinase) with an IC50 of 0.61 μM. It demonstrates significant inhibitory activity against the colorectal cancer cell line HCT116, making it a valuable tool for studying TNIK's role in oncogenic signaling pathways. This reagent is suited for research applications focused on cancer biology and targeted therapeutic development.

Alpha 1 Antichymotrypsin, Human Plasma is a serine protease inhibitor involved in various physiological processes. Its presence in amyloid lesions is associated with Alzheimer’s disease, making it a significant marker in neurodegenerative research. This reagent is valuable for studies focused on Alzheimer's disease pathophysiology and related therapeutic investigations.

Patamostat hydrochloride is a highly effective protease inhibitor, targeting trypsin, plasmin, and thrombin with IC50 values of 39 nM, 950 nM, and 1.9 μM, respectively. It demonstrates potential in suppressing the pathogenesis and progression of acute pancreatitis, making it a valuable tool for research focused on protease-related diseases and therapeutic interventions.

Roseoside is a potent inhibitor targeting the HCV NS5A/B replicase, demonstrating an IC50 of 20 μM. This compound effectively interferes with HCV RNA replication in vitro and exhibits antibacterial properties against both Gram-positive and Gram-negative bacteria, as well as antifungal activity against Candida albicans. Roseoside serves as a valuable research tool for investigating bacterial infections, candidiasis, and Hepatitis A and C virus mechanisms, while demonstrating no cytotoxic effects in human systems.

HTRA1-IN-1 is a potent and selective inhibitor of high temperature requirement A serine peptidase 1 (HTRA1) with an IC50 of 13 nM. This compound is instrumental in research related to HTRA1-associated conditions, including age-related macular degeneration (AMD), osteoarthritis, and rheumatoid arthritis. By inhibiting HTRA1, it offers potential insights into therapeutic strategies for these diseases.